New Bill Opens Gene Therapy Access for Rare Disease Patients

When Kendra Riley's daughters were diagnosed with a fatal genetic disease, she faced an impossible choice: watch them die or raise half a million dollars to move her family to Italy for treatment that existed but wasn't available in America.

Congress wants to make sure no family faces that heartbreak again. Representatives Diana Harshbarger and Senator Ron Johnson just introduced the Right to Try for Individualized Treatments Act, a bill that would give patients with rare diseases direct access to cutting-edge gene therapies.

The legislation builds on a 2018 law that already helps terminally ill patients access experimental drugs. But medical science has changed dramatically since then. Today's treatments can be designed for a single patient's unique genetic code, and current regulations weren't built for that level of personalization.

Under the new bill, patients wouldn't need to beg federal regulators for permission to try therapies their doctors believe could save their lives. They could access gene and cell therapies tailored specifically to their condition, even before the treatments complete the full FDA approval process.

The need is urgent. Families are already traveling overseas because other countries approve these personalized treatments faster than the United States does. Some are crowdfunding hundreds of thousands of dollars just for the chance to try therapies that could cure diseases once considered death sentences.

Nearly 20 states have already passed their own protections for personalized medicine access. The federal bill would create a uniform pathway across the country, ensuring that where you live doesn't determine whether you can access life-saving care.

Why This Inspires

This isn't just about changing regulations. It's about parents like Kendra Riley who shouldn't have to choose between bankruptcy and their child's survival.

Medical innovation is racing ahead at breathtaking speed. Gene therapies can now target diseases so rare they affect only a handful of people worldwide. But outdated approval processes treat these personalized cures the same as mass-produced pills, creating barriers that cost time families don't have.

The original Right to Try law proved that patients can safely access experimental treatments when they're out of options. This expansion recognizes that the future of medicine isn't one-size-fits-all, and our laws shouldn't be either.

For families watching their children struggle with rare genetic diseases, this bill represents something more valuable than policy reform: it represents hope that the cure might not require an ocean crossing, a second mortgage, or watching the calendar run out while waiting for bureaucratic approval.

The legislation puts medical decisions back where they belong, between patients, their families, and their doctors.